APC and cancer: Based on the Axin-derived peptide that binds to β-catenin, a stapled peptides xStAx was reported to impair Wnt/β-catenin signaling.183 Recently, β-catenin-targeting degrader 115 (xStAx-VHLL, Fig. 27) was developed by coupling xStAx with the VHL ligand to achieve efficient β-catenin degradation.184 Although they had clinical limitations as peptide-based PROTACs, they still displayed long-term degradation of β-catenin and strong inhibition of Wnt/β-catenin signaling in cancer cells and in APC/organoids.